Back to Agenda
Unlocking the Potential of Pharmacogenomics for Reducing the Burden of Adverse Drug Reactions
Session Chair(s)
Alison Cave
Chief Safety Officer, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
This session will explore current progress in pharmacogenomics; the barriers and opportunities it represents for drug safety from the perspective of medicines regulators, industry, the scientific community, healthcare professionals, and patients.
Learning Objective : Discuss the importance of pharmacogenomics for introducing better risk mitigation strategies; Appraise progress being made in this field internationally; Recognize opportunities for introduction of pharmacogenomic research in your organization.
Speaker(s)
Alison Cave
Chief Safety Officer, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
From Post-Marketing Reports of Side Effects to Pharmacogenomic Research: Can we Reduce the Burden of ADRs?
Christine Marie Von Raesfeld
Board member/community liaison, The Light Collective, United States
Patient Perspective
Gregory Powell, PHARMD, MBA
Senior Director, Safety and Clinical Innovation, GlaxoSmithKline, United States
Industry Perspective
Kathleen M. Giacomini, PHD
Dean, School of Pharmacy, Professor and Principal Investigator, University of California San Francisco, United States
Academic Perspective
Have an account?